A comparative study in the Indian patients of geographic atrophy for the efficacy and safety for the AREDS 2 Formula, the combination of Vitamin C, Copper, Zeaxanthin, Zinc, Lutein, and Vitamin E, with the combination of L-Glutathione, Lutein (contains Zeaxanthin) and Astaxanthin

Author:

Pawaskar LalitORCID,Sharma AmitORCID,Kiran Mayuresh

Abstract

Geographic atrophy (GA) is the main reason of blindness in people above 60 years. During this study, the efficacy and safety of two different combinations including Investigational product 1 (IP-1) combination of Vitamin C, Copper, Lutein, Zinc, Zeaxanthin, and Vitamin E vs Investigational product (IP-2) combination of Lutein (which contains Zeaxanthin), L-Glutathione and Astaxanthin was compared in for the indication of GA. On day 30, 180, and 365 all the recruited clinical trial subjects were required to visit the clinical trial site, with day 0 serving as the baseline visit. Patients assigned to IP-1 were categorized as group C patients, whereas those assigned to IP-2 were categorized as group D patients. Visual acuity (VA), vision-related quality of life (VRQOL), and the vision impairment questionnaire (VIQ) were used as efficacy assessment measures. Based on the patients' reported adverse events, a safety assessment was done.Statistically significant increase was not found in patients randomized to IP-1in VA (p=0.6229) and VRQOL (p=0.1772) and no statistically significant reduction in VIQ score (p = 0.2503). In patients randomized to IP-2, there was statistically significant increase in VA (p<0.0001), statistically significant reduction in VRQOL (p=0.0036) and no significant increase in VIQ (p=0.5993). In both groups there was statistically significant difference in VA (p=0.0134) and VRQOL (p=0.0045) and no statistically significant difference in VIQ (p=0.2787). IP-1 was more effective than IP-2 in terms of maintaining VA (p=0.0134) and VRQOL (p=0.0045), however there was no statistically significant difference in the effectiveness of the two products for VIQ (p=0.2787) in patients of GA.

Publisher

IP Innovative Publication Pvt Ltd

Subject

Ophthalmology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3